NIH RAC REVIEW GROUP SUGGESTS GENE THERAPY CANCER PROTOCOLS MAY NEED TO EVALUATE TUMOR REDUCTION AS WELL AS TOXICITY IN MODIFIED PHASE I TRIALS
Gene therapy cancer protocols being reviewed by the National Institute's of Health Recombinant DNA Advisory Committee may need to assess tumor reduction as well as toxicity, members of the ad hoc review committee to RAC asserted at their first meeting Feb. 3.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth